Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

A randomised, double-blind, controlled efficacy trial of the LiESP/QA-21 vaccine in naïve dogs exposed to two leishmania infantum transmission seasons.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101291488 Publication Model: eCollection Cited Medium: Internet ISSN: 1935-2735 (Electronic) Linking ISSN: 19352727 NLM ISO Abbreviation: PLoS Negl Trop Dis Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Dog Diseases/*prevention & control ; Endemic Diseases/*veterinary ; Leishmania infantum/*immunology ; Leishmaniasis Vaccines/*administration & dosage ; Leishmaniasis, Visceral/*veterinary; Animals ; Dog Diseases/immunology ; Dog Diseases/transmission ; Dogs ; Double-Blind Method ; Endemic Diseases/prevention & control ; Female ; Insect Vectors/parasitology ; Italy ; Leishmania infantum/genetics ; Leishmaniasis, Visceral/prevention & control ; Leishmaniasis, Visceral/transmission ; Male ; Phlebotomus/parasitology ; Spain
    • Abstract:
      Canine leishmaniasis is an important zoonosis caused by uncontrolled infection with Leishmania infantum, where an inappropriate immune response is not only responsible for permitting this intracellular parasite to multiply, but is also responsible for several of the pathological processes seen in this disease. Effective canine vaccines are therefore a highly desirable prevention tool. In this randomised, double-blinded, controlled trial, the efficacy of the LiESP/QA-21 vaccine (CaniLeish, Virbac, France) was assessed by exposing 90 naïve dogs to natural L. infantum infection during 2 consecutive transmission seasons, in two highly endemic areas of the Mediterranean basin. Regular PCR, culture, serological and clinical examinations were performed, and the infection/disease status of the dogs was classified at each examination. The vaccine was well-tolerated, and provided a significant reduction in the risk of progressing to uncontrolled active infection (p = 0.025) or symptomatic disease (p = 0.046), with an efficacy of 68.4% and a protection rate of 92.7%. The probability of becoming PCR positive was similar between groups, but the probability of returning to a PCR negative condition was higher in the vaccinated group (p = 0.04). In conclusion, we confirmed the interest of using this vaccine as part of a comprehensive control program for canine leishmaniasis, and validated the use of a protocol based on regular in-depth assessments over time to assess the efficacy of a canine leishmaniasis vaccine.
    • Comments:
      Erratum in: PLoS Negl Trop Dis. 2014 Nov;8(11):e3408.
    • References:
      Vet Parasitol. 2011 Sep 8;181(1):23-30. (PMID: 21570192)
      Med Vet Entomol. 1987 Oct;1(4):339-42. (PMID: 2979550)
      Adv Parasitol. 2004;57:1-88. (PMID: 15504537)
      J Parasitol. 2005 Aug;91(4):970-2. (PMID: 17089780)
      Trends Parasitol. 2002 Sep;18(9):399-405. (PMID: 12377257)
      Vet Res. 2014 Jun 25;45:69. (PMID: 24964736)
      Vet Immunol Immunopathol. 2009 Mar 15;128(1-3):67-70. (PMID: 19054573)
      J Am Vet Med Assoc. 2010 Jun 1;236(11):1184-91. (PMID: 20513195)
      PLoS Negl Trop Dis. 2012;6(6):e1683. (PMID: 22724031)
      Vet Immunol Immunopathol. 2005 Jul 15;106(3-4):247-57. (PMID: 15963823)
      PLoS One. 2012;7(5):e35671. (PMID: 22693548)
      Am J Trop Med Hyg. 2001 Mar-Apr;64(3-4):119-24. (PMID: 11442205)
      Vet Parasitol. 2009 Mar 9;160(1-2):55-9. (PMID: 19046812)
      Infect Immun. 1994 Jan;62(1):229-35. (PMID: 8262632)
      Trends Parasitol. 2008 Jul;24(7):324-30. (PMID: 18514028)
      Acta Trop. 1994 Sep;57(4):333-5. (PMID: 7810389)
      J Clin Microbiol. 2006 Apr;44(4):1318-22. (PMID: 16597857)
      Vet Parasitol. 2012 Oct 26;189(2-4):189-96. (PMID: 22575278)
      Vet Pathol. 2003 Nov;40(6):677-84. (PMID: 14608021)
      Res Vet Sci. 2006 Aug;81(1):68-75. (PMID: 16288789)
      Vet Dermatol. 2009 Oct;20(5-6):471-89. (PMID: 20178485)
      Vet Parasitol. 2006 Apr 15;137(1-2):159-67. (PMID: 16414196)
      Trans R Soc Trop Med Hyg. 1994 Jul-Aug;88(4):491-3. (PMID: 7570854)
      Vet Immunol Immunopathol. 2002 Sep 6;88(1-2):21-30. (PMID: 12088641)
      Vaccine. 2008 Oct 29;26(46):5888-95. (PMID: 18786587)
      Am J Trop Med Hyg. 1996 Aug;55(2):125-30. (PMID: 8780448)
      Vet Parasitol. 2009 Oct 28;165(1-2):1-18. (PMID: 19559536)
      PLoS Negl Trop Dis. 2013 May 09;7(5):e2225. (PMID: 23675551)
      J Am Vet Med Assoc. 2010 Jun 1;236(11):1200-6. (PMID: 20513198)
      Vaccine. 2002 Sep 10;20(27-28):3277-84. (PMID: 12213397)
      J Clin Microbiol. 2006 Jul;44(7):2343-7. (PMID: 16825347)
      Vet Immunol Immunopathol. 2008 Jun 15;123(3-4):353-9. (PMID: 18406470)
      Parasit Vectors. 2011 Apr 13;4:52. (PMID: 21489241)
      Vet Dermatol. 2005 Jun;16(3):187-91. (PMID: 15960633)
      Vaccine. 2007 May 22;25(21):4223-34. (PMID: 17395339)
      Vaccine. 2005 Nov 1;23(45):5245-51. (PMID: 16054272)
      Lancet Infect Dis. 2002 Aug;2(8):494-501. (PMID: 12150849)
      Trends Parasitol. 2013 Jul;29(7):339-45. (PMID: 23746747)
      Vet Immunol Immunopathol. 2014 Apr 15;158(3-4):199-207. (PMID: 24560650)
      Vet Parasitol. 2013 Nov 8;197(3-4):691-5. (PMID: 23747102)
    • Accession Number:
      0 (Leishmaniasis Vaccines)
    • Publication Date:
      Date Created: 20141010 Date Completed: 20160329 Latest Revision: 20211021
    • Publication Date:
      20250114
    • Accession Number:
      PMC4191955
    • Accession Number:
      10.1371/journal.pntd.0003213
    • Accession Number:
      25299614